Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Table 6 Studies describing intensive care unit length of stay in patients with resistant and multidrug-resistant Pseudomonas aeruginosa infections

Author	Study groups (n)	Median ICU Length of Stay (days)	Reported Significance (p-value or 95% CI)	Ref
Author	Study groups (n)	Main findings	Reported Significance (p-value or 95% CI)	Ref
Evans et al. (2007)	Susceptible P. aeruginosa (73)	6	0.02	[71]
Evans et al. (2007)	Resistant P. aeruginosa^c (47)	13	0.02	[71]
Kaminski et al. (2011)	Ureido/carboxypenicillin resistant P. aeruginosa (70)	29	0.37	[66]
Kaminski et al. (2011)	Ureido/carboxypenicillin susceptible P. aeruginosa (153)	28.5	0.37	[66]
Paramythiotou et al. (2004)	MDR P. aeruginosa^d (34)	44.5 (57.0)^a,b	0.55	[54]
Paramythiotou et al. (2004)	Control (34)	43.5 (46.9)^a,b	0.55	[54]

^a Length of ICU stay (ICU stay matched between cases and controls); ^b Study reported mean length of stay; ^c Absence of susceptibility to all the drugs in one or more of the following antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and fluoroquinolones; ^d Absence of susceptibility to piperacillin, ceftazidime, imipenem, and ciprofloxacin.

ISSN: 2047-2994